Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

6.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.5K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

4.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.9K
Coagulation01:09

Coagulation

5.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
5.6K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

5.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.3K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

2.6K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.6K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Medical Microbiology
  9. Medical Infection Agents (incl. Prions)
  11. Erpy-like Protein Interaction With Host Thrombin And Fibrinogen Intervenes The Plasma Coagulation Through Extrinsic And Intrinsic Pathways

ErpY-like Protein Interaction with Host Thrombin and Fibrinogen Intervenes the Plasma Coagulation through Extrinsic and Intrinsic Pathways

Saswat Hota1, Manish Kumar1

  • 1Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India.

ACS Infectious Diseases
|September 4, 2024

Related Experiment Videos

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

708
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

438
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

18.9K

View abstract on PubMed

Summary
This summary is machine-generated.

Pathogenic Leptospira uses ErpY-like lipoprotein to evade host defenses. This protein inhibits blood clotting by interfering with fibrinogen and thrombin, increasing bacterial virulence.

Area of Science:

  • Microbiology
  • Biochemistry
  • Hematology

Background:

  • Pathogenic *Leptospira* survival relies on complex host interactions.
  • The outer membrane ErpY-like lipoprotein enhances *Leptospira* pathogenicity.
  • ErpY-like protein aids immune evasion by interacting with host complement regulators.

Purpose of the Study:

  • To investigate the role of recombinant ErpY-like protein (rErpY-like) in host coagulation.
  • To determine the effect of rErpY-like on plasma clotting and thrombin activity.
  • To elucidate the mechanism by which ErpY-like protein contributes to leptospiral virulence.

Main Methods:

  • Assessed the impact of rErpY-like on bovine and human plasma clotting.
  • Measured clot density, viscoelastic properties, and clotting rate.
Keywords:
ErpY-like proteinLeptospirafibrinogenplasma clot

Related Experiment Videos

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

708
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

438
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

18.9K
  • Investigated inhibition of thrombin-catalyzed fibrin formation and thrombin binding affinity.

    • Main Results:

    • rErpY-like protein reduced clot density and altered viscoelastic properties in a concentration-dependent manner.
    • The protein significantly diminished the average clotting rate in plasma.
    • rErpY-like protein inhibited thrombin-catalyzed fibrin formation and showed saturable binding to thrombin.

    Conclusions:

    • The ErpY-like lipoprotein possesses anticoagulant properties.
    • This anticoagulant activity, via interaction with fibrinogen and thrombin, contributes to *Leptospira* pathogenicity.
    • ErpY-like protein is a significant virulence factor in leptospiral infections.
    thrombin